MRNA-LNP vaccine encoding the <i>Plasmodium vivax</i> circumsporozoite protein is highly immunogenic and confers protection in mice.

ABSTRACT: Plasmodium vivax poses significant challenges to malaria control due to its relapsing nature. This study explores the immunogenicity and efficacy of nucleoside-modified mRNA-lipid nanoparticle (LNP) vaccines targeting the P. vivax circumsporozoite protein (PvCSP). Two mRNA constructs encoding PvCSP were designed and tested in mice. Despite lower protein expression, the vaccine encoding the wild-type signal peptide (SP) and glycosylphosphatidylinositol (GPI) anchor of PvCSP induced significantly higher antibody titers against the PvCSP and its repeat region compared with the mRNA construct with SP but without GPI. The immunogenicity of PvCSP mRNA-LNP vaccines was evaluated using various administration routes and immunization schedules. Both intradermal and intramuscular

SUBMITTER: Limsalakpetch A 

PROVIDER: S-EPMC12359152 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature